# Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

> **NCT04861467** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 155 (estimated)

## Conditions studied

- HNSCC

## Interventions

- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT04861467
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-01
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 155 (ESTIMATED)
- **Last updated:** 2021-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04861467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04861467, "Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04861467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*